Novartis AG 2017 AR2
The report highlights Novartis' solid performance in 2017, with net sales reaching USD 49.1 billion, driven by key growth products like Cosentyx and Entresto. The company successfully launched three innovative cancer therapies, including Kymriah, the first approved CAR-T cell therapy. In sustainability, Novartis expanded its Novartis Access program to six countries, delivering over 685,000 treatments for chronic diseases in lower-income nations. Additionally, the company reduced its total Scope 1 and Scope 2 greenhouse gas emissions to 1,259.9 thousand tonnes and was recognized in major sustainability rankings.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2017
Type: AR2
Pages: 280
Back to company
Novartis AG
Annual Report
The report highlights Novartis' solid performance in 2017, with net sales reaching USD 49.1 billion, driven by key growth products like Cosentyx and Entresto. The company successfully launched three innovative cancer therapies, including Kymriah, the first approved CAR-T cell therapy. In sustainability, Novartis expanded its Novartis Access program to six countries, delivering over 685,000 treatments for chronic diseases in lower-income nations. Additionally, the company reduced its total Scope 1 and Scope 2 greenhouse gas emissions to 1,259.9 thousand tonnes and was recognized in major sustainability rankings.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees